This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Naoumova, R. P. Articles by Camici, P. G. Search for Related Content PubMed Articles by Naoumova, R. P. Articles by Camici, P. G. Related Collections Related Article

Pioglitazone Improves Myocardial Blood Flow and Glucose Utilization in Nondiabetic Patients With Combined Hyperlipidemia

A Randomized, Double-Blind, Placebo-Controlled Study

Rossi P. Naoumova, MD, PhD, FAHA, MRCP^_*, Heiko Kindler, MD, MRCP^_*, Lucia Leccisotti, MD^_*,, Marco Mongillo, MD, PhD^_*, Muhammad T. Khan, MD, FRCS^_*, Clare Neuwirth, RN^_*, Mary Seed, MA, DM, FRCPath, FREP, Paul Holvoet, PhD, FAHA, John Betteridge, PhD, MD, FAHA, FRCP^|| and Paolo G. Camici, MD, FESC, FACC, FAHA, FRCP^_*,#,_*

^_* Medical Research Council Clinical Sciences Centre, Imperial College, Hammersmith Hospital, London, United Kingdom
^# National Heart and Lung Institute, Imperial College, Hammersmith Hospital, London, United Kingdom
Institute of Nuclear Medicine, Catholic University of the Sacred Heart, Rome, Italy
Lipid Clinic, Charing Cross Hospital, London, United Kingdom
Department of Cardiovascular Diseases, Faculty of Medicine, Katholieke Universiteit Leuven, Leuven, Belgium
^|| Department of Medicine, University College London, University College Hospitals, London, United Kingdom. Supported in part by an unrestricted grant from Takeda Europe.

View larger version (6K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Diagram Depicting the Study Protocol With the Relative Timings Thin arrows = hospital visits when blood pressure, pulse, and body weight were checked and fasting blood sample obtained; thick arrows = positron emission tomography (PET) scans; thick line = study medication (placebo/pioglitazone) with randomization at visit 2; stethoscope = physical examination.

View larger version (14K): [in this window] [in a new window] [Download PPT slide]   Figure 2 M and MGU in Placebo and Pioglitazone Groups at Baseline and After Treatment After treatment, significant increases in whole body glucose disposal (M) and myocardial glucose utilization (MGU) were obtained only in the pioglitazone group. Error bars indicate SEM. *p < 0.05 for treatment differences between the placebo and pioglitazone groups.

View larger version (10K): [in this window] [in a new window] [Download PPT slide]   Figure 3 Hyperemic MBF in Placebo and Pioglitazone Groups at Baseline and After Treatment After treatment, a significant increase in hyperemic myocardial blood flow (MBF) was observed in the pioglitazone group. Error bars indicate SEM. *p < 0.05 within-treatment effect.